Published in:
Open Access 01-12-2015 | Research article
Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients
Published in: BMC Cancer | Issue 1/2015
Login to get accessAbstract
Background
Although new individual treatments continue to reshape the landscape of clinical care in patients with lung cancer, most of the progress has been mainly of benefit to patients with lung adenocarcinomas rather than squamous cell lung carcinoma (SQCLC). Our study aimed to determine whether the epidermal growth factor receptor (EGFR) gene mutation is present in pure SQCLC. We further determined the mutation frequency and the clinical and pathological features of groups that are in high risk for EGFR mutation.
Methods
A total of 185 Chinese patient specimens diagnosed as SQCLC in the Shanghai Chest Hospital at the Shanghai Jiao Tong University were selected for this study. Hematoxylin-eosin stained slides for all cases were reviewed and evaluated by immunohistochemical analysis with the aim of selecting samples with pure SQCLC. After screening, 22 cases were eliminated and 163 pure SQCLC cases remained. Amplification Refractory Mutation System was used to detect the EGFR gene mutation status in the 163 SQCLC specimens.
Results
A total of 28 cases with EGFR mutation were detected among the 163 specimens. The EGFR mutation rate was 17.2% (28/163). Sex and smoking status were significantly associated with the status of EGFR gene mutation (P = 0.022 and P = 0.049, respectively). Age and degree of differentiation were not significantly correlated to EGFR mutation (P = 0.730 and P = 0.651, respectively).
Conclusions
EGFR mutations are present in pure SQCLC, which are more frequently detected in females and nonsmoker patients. Our results indicate the importance for all patients with SQCLC to have EGFR mutation status examined. These patients with activating EGFR mutation could accept tyrosine kinase inhibitors (TKIs) treatment.